Jonathan Lieber Net Worth

The estimated Net Worth of Jonathan I Lieber is at least $60 Tysiąc dollars as of 7 June 2022. Mr. Lieber owns over 37,500 units of Salarius Pharmaceuticals stock worth over $60,000 and over the last 12 years he sold SLRX stock worth over $0. In addition, he makes $0 as Independent Director at Salarius Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lieber SLRX stock SEC Form 4 insiders trading

Jonathan has made over 2 trades of the Salarius Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 37,500 units of SLRX stock worth $7,125 on 7 June 2022.

The largest trade he's ever made was buying 37,500 units of Salarius Pharmaceuticals stock on 7 June 2022 worth over $7,125. On average, Jonathan trades about 2,500 units every 118 days since 2013. As of 7 June 2022 he still owns at least 37,500 units of Salarius Pharmaceuticals stock.

You can see the complete history of Mr. Lieber stock trades at the bottom of the page.

Jonathan Lieber biography

Jonathan I. Lieber serves as Independent Director of the Company. Since December 2018, Mr. Lieber has been a Managing Director of Danforth Advisors LLC, a firm that provides strategic CFO advisory and outsourced accounting services to healthcare companies. In that capacity, he is currently serving as interim CFO for a number of healthcare companies. From July 2015 through September 2019, Mr. Lieber was Chief Financial Officer of Histogenics Corporation (NASDAQ: HSGX) a cell therapy company developing products for the orthopedics market. Prior to Histogenics, Mr. Lieber was Senior Vice President and Chief Financial Officer of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, from January 2014 to June 2015. From September 2012 to September 2013, Mr. Lieber served as the Chief Financial Officer and Treasurer of Repligen Corporation, a manufacturer and supplier of high-value consumables to the life sciences industry. From June 2009 to until its acquisition by GE Healthcare in May 2012, Mr. Lieber served as Chief Financial Officer and Treasurer of Xcellerex, Inc. a privately held company engaged in the manufacture and sale of capital equipment and related consumables to the biopharmaceutical industry. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration from Boston University.

How old is Jonathan Lieber?

Jonathan Lieber is 51, he's been the Independent Director of Salarius Pharmaceuticals since 2020. There are 8 older and no younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.

What's Jonathan Lieber's mailing address?

Jonathan's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.

Insiders trading at Salarius Pharmaceuticals

Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum oraz Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.

What does Salarius Pharmaceuticals do?

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Complete history of Mr. Lieber stock trades at Applied Genetic Technologies Corp, Repligen oraz Salarius Pharmaceuticals

Salarius Pharmaceuticals executives and stock owners

Salarius Pharmaceuticals executives and other stock owners filed with the SEC include:

• William McVicar,
  Chairman of the Board
• David J. Arthur M.B.A.,
  CEO, Pres & Director
• David Arthur,
  President, Chief Executive Officer, Director
• Mark Rosenblum,
  Chief Financial Officer, Executive Vice President - Finance
• Mark J. Rosenblum,
  Exec. VP of Fin. & CFO
• Maureen McEnroe,
  IR Contact Officer
• Jonathan Lieber,
  Independent Director
• Arnold Hanish,
  Independent Director
• Tess Burleson,
  Independent Director
• Paul Lammers,
  Lead Independent Director
• Bruce McCreedy,
  Interim Chief Scientific Officer and Director
• Nadeem Mirza,
  Senior Vice President - Clinical Development
• Dr. Daniela Y. Santiesteban,
  Director of Research and Bus. Devel.
• Dr. Nadeem Q. Mirza M.D., M.P.H.,
  Sr. VP of Clinical Devel.
• Jonathan P Northrup,
  Director
• Pao Yu Chuang,
  Controller
• Scott Jordan,
  Chief Financial Officer